Myelodysplastic Syndromes
April 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Authors:Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, Li M, Zhan X, Li W
Institution:Department of Hematology, The First Hospital of Jilin University, Changchun, China. China. China. China. China. Electronic address: jdyylw@163.com.
Journal:Crit Rev Oncol Hematol. 2018 Feb;122:123-132. doi: 10.1016/j.critrevonc.2017.12.013. Epub 2018 Jan 3.

2:Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.; Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.; Department of Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.; Med. Clinic III, University Medicine Mannheim, Mannheim, Germany.
Journal:Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18.

3:Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
Authors:Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luno E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Diez-Campelo M, Ortega M, Valcarcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D
Institution:Hospital Plato, Barcelona, Spain; Fundacio Clinic per la Recerca Biomedica, Barcelona, Spain. Electronic address: Meritxell.nomdedeu@gmail.com.; Hospital Clinic-IDIBAPS, Barcelona, Spain.; Hospital del Mar, Barcelona, Spain.; Josep Carreras Leukemia Research Institute, Campus Badalona, Spain.; Hospital Central de Asturias, Oviedo. Spain.
Journal:Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28.

4:Gene expression and risk of leukemic transformation in myelodysplasia.
Authors:Shiozawa Y, Malcovati L, Galli A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellstrom-Lindberg E, Miyano S, Cazzola M, Ogawa S
Institution:Department of Pediatrics, The University of Tokyo, Tokyo, Japan. Pavia, Italy. Pavia, Italy. Sciences, Radcliffe Department of Medicine, University of Oxford, and Oxford BRC Haematology Theme, Oxford, United Kingdom. Karolinska Institutet, Stockholm, Sweden. Sciences, Radcliffe Department of Medicine, University of Oxford, and Oxford BRC Haematology Theme, Oxford, United Kingdom. Karolinska Institutet, Stockholm, Sweden. Science, The University of Tokyo, Tokyo, Japan. Pavia, Italy.
Journal:Blood. 2017 Dec 14;130(24):2642-2653. doi: 10.1182/blood-2017-05-783050. Epub 2017 Nov 2.

5:Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Authors:Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB
Institution:Robert J. Soiffer, Haesook T. Kim, Vincent T. Ho, Edwin P. Alyea, and Jerome Ritz, Dana-Farber Cancer Institute; James D. Levine, Beth Israel Deaconess Medical Center and Harvard Medical School; Yi-Bin Chen, Massachusetts General Hospital, Boston; Frank Glavin, Neovii Biotech, Lexington, MA; Joseph McGuirk, University of Kansas Medical Center, Kansas City, KS; Mitchell E. Horwitz, Duke University Medical Center, Durham; Thomas C. Shea, University of North Carolina School of Medicine, Chapel Hill, NC; Laura Johnston, Stanford University, Stanford, CA; Mrinal M. Patnaik, Mayo Clinic, Rochester, MN; Witold Rybka, Penn State College of Medicine, Hershey; David L. Porter, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Andrew Artz, University of Chicago, Chicago; Patrick J. Stiff, Loyola University Medical Center, Maywood, IL; Michael W. Boyer, University of Utah, Salt Lake City, UT; Richard T. Maziarz, Oregon Health & Science University, Portland, OR; Paul J. Shaughnessy, Texas Transplant Institute, San Antonio; Madhuri Vusirikala, University of Texas Southwestern Medical Center, Dallas, TX; Usama Gergis, Weill Cornell Medical College; Ran Reshef, Columbia University Medical Center, New York, NY; Hana Safah, Tulane University, New Orleans, LA; John F. DiPersio and Peter Westervelt, Washington University School of Medicine, St Louis, MO; Jeff Szer, Royal Melbourne Hospital, Parkville, Victoria; Ian D. Lewis, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Jennifer Holter, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Paul J. Martin, Fred Hutchinson Cancer Research Center, Seattle, WA; Joseph A. Pidala, H. Lee Moffitt Cancer Center, Tampa, FL; and Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, TN.
Journal:J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.

6:Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.
Authors:Lang F, Wunderle L, Pfeifer H, Schnittger S, Bug G, Ottmann OG
Institution:Department of Hematology/Oncology, Goethe University Hospital, Frankfurt am Main, Germany. Germany. Germany. Germany. Wales, United Kingdom.
Journal:Am J Case Rep. 2017 Oct 16;18:1099-1109.

7:Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.
Authors:Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, Tsuchiya S, Ohyashiki K, Miyazaki Y
Institution:Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan. Japan. Gerontology, Tokyo, Japan. Shimotsuke, Japan. Hospital, Tokyo, Japan.
Journal:Cancer Sci. 2017 Dec;108(12):2445-2453. doi: 10.1111/cas.13409. Epub 2017 Oct 25.

8:A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
Authors:Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M
Institution:Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan.; Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Journal:Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28.

9:Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Authors:Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Institution:Universitatsklinikum "Carl Gustav Carus" der Technischen Universitat Dresden, Dresden, Germany. Electronic address: uwe.platzbecker@uniklinikum-dresden.de. Dusseldorf, Dusseldorf, Germany. Germany.
Journal:Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.

10:Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Authors:Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H
Institution:Department of Hematology and Oncology and. Mie, Japan. Mie, Japan. School of Medicine, Ehime University, Ehime, Japan. Medicine, Aichi, Japan. Japan. Sciences, Nagasaki, Japan; and. School of Medicine, Ehime University, Ehime, Japan. Medicine, Aichi, Japan. Medicine, Aichi, Japan. Japan. Medicine, Aichi, Japan. Japan. School of Medicine, Ehime University, Ehime, Japan. Mie, Japan.
Journal:Blood. 2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202. Epub 2017 Aug 31.

11:Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Authors:Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Graduate Medical School Singapore, Singapore General Hospital, Singapore. National University Hospital, Singapore. National University Hospital, Singapore. Comprehensive Cancer Center, Madison, Wisconsin. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas.
Journal:Cancer. 2017 Dec 15;123(24):4851-4859. doi: 10.1002/cncr.30949. Epub 2017 Aug 25.

12:A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
Authors:Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD
Institution:Department of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Journal:Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31.

13:Preclinical modeling of myelodysplastic syndromes.
Authors:Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D
Institution:Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK. London, UK. London, UK. London, UK. London, UK. London, UK.
Journal:Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

14:Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Authors:Glasser CL, Lee A, Eslin D, Marks L, Modak S, Glade Bender JL
Institution:*Department of Pediatric Hematology/Oncology, Winthrop University Medical Center, Mineola daggerDepartment of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York Presbyterian Hospital section signDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY double daggerDepartment of Pediatric Hematology/Oncology, Arnold Palmer Hospital for Children, Orlando, FL.
Journal:J Pediatr Hematol Oncol. 2017 Oct;39(7):560-564. doi: 10.1097/MPH.0000000000000868.

15:A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
Authors:Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG
Institution:The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

16:The burden of autoimmunity in myelodysplastic syndromes.
Authors:Fozza C
Institution:Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
Journal:Hematol Oncol. 2018 Feb;36(1):15-23. doi: 10.1002/hon.2423. Epub 2017 Apr 27.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 10, 2018
178 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS93001576

Coupon Expires: June 21, 2018



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.